NENikolay M. Ershov

Nikolay M. Ershov

*This is an algorithmically generated author record based on publicly available information.

Nikolay M. Ershov has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • REHABILITATION FEATURES OF PATIENTS WITH GORHAM-STOUT SYNDROME

    by О.а. Нисиченко, В.а. Бондаренко, И.р. Минулин, Н.м. Ершов, Е.в. Жуковская

    Авторы описывают актуальность описания диагностики и лечения редкого заболевания синдрома (Gorham–Stout) Горхема-Стоута, приводят клиническое наблюдение за пациентом Национального медицинского исследовательского центра детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева, обсуждают необходимые реабилитационные мероприятия пациентов. The authors describe the relevance of the description of the diagnosis and treatment of a rare disease of Gorham-Stout syndrome (Gorham-Stout), provide clinical observation of the patient of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, and discuss the necessary rehabilitation measures for patients.


  • Open Access

    Essential thrombocythemia in children and adolescents — analysis of 31 cases

    by N. M. Ershov, М. В. Гаськова, A. V. Pshonkin, Yu. V. Olshanskaya, T. V. Konyukhova, D. S. Abramov, P. A. Levin, A. V. Poletaev, E. A. Seregina, S. A. Plyasunova, et al.

    Introduction. Essential thrombocythemia is an extremely rare disorder in childhood. This disease is characterized by a persistent increase in the peripheral blood platelet count, associated with a proliferation of atypical megakaryocytes in the bone marrow.Aim— to analyze the clinical features of the course of essential thrombocythemia (ET) and the response to therapy in pediatric and adolescent patientsMaterials and methods. Thirty-one patients with ET under the age of 21 years were analyzed. All patients were diagnosed with ET in accordance with WHO criteria on the basis of an examination, including assessment of clinical data, laboratory tests (general clinical tests; morphological, genetic, and histological examinations of bone marrow), instrumental studies, and an assessment of response to treatment.Results. The average age of disease onset was 9 years 9 months, with a median of 9 years 6 months. Organomegaly was recorded in 16 (52 %) patients, of whom 6 (37.5 %) had isolated splenomegaly and 6 (37.5 %) had hepatosplenomegaly. Bleeding was noted in 6 (19.4 %) patients with a deep decrease in vWF:RCo (no more than 15 %) and an extreme increase in platelets (PLT) (more than 2000 × 109/L). Twelve (38.7 %) patients suffered from microcirculation disorders (headaches, dizziness, melalgia), half of them had a platelet count of 1000–2000 × 109/L, which is comparable to asymptomatic patients. No thrombosis was registered in our group. TheJAK2V617Fmutation was detected in 3 (9.7 %) patients, a mutation in theCALRgene was found in 9 (29.0 %) of patients, there was a mutation in theMPLgene in one (3.2 %) patient, and in the remaining cases (18 (58.1 %) patients), there was no damage to typical driver genes. Translocation t(12;12) was revealed in 1 (3.2 %) patient. The response to one-component cytoreductive therapy (CR+PR) was found to be quite high in young patients and constituted about 70–80 %. The complete response rate (CR) was as follows, respectively: 42.9 % (3) — to anagrelide therapy (ANA), 47.4 % (9) — to interferon therapy (INF), and 0 % — to hydroxycarbamide (HU). However, HU was not used in the fi rst line of therapy for the children in our group.Conclusion. In the pediatric population, ET patients are dominated by the group of “triple-negative” disease, which somewhat complicates the differential diagnosis with secondary thrombocytosis. Compared to the adult population, the risk of bleeding is higher for pediatric patients, which is associated with the large number of patients with extremely high levels of platelets. In the case of hemorrhagic syndrome development or microcirculatory disorders that cannot be stopped by taking antiplatelet agents, we recommend giving preference to INF and HU as fi rst-line therapy, due to the peculiarities of pharmacokinetics and the potential risk of progression of myelofi brosis during ANA therapy.


  • Open Access

    Incidence of venous thromboembolism in children with primary lymphomas

    by D. A. Evstratov, L. H. Anderzhanova, A. V. Pshonkin, Yu. G. Abugova, N. V. Myakova, P. A. Zharkov, V. V. Fominykh, N. M. Ershov, Yu. Yu. Dyakonova, L. A. Vavilova, et al.

    Cancer increases the risk of venous thromboembolism (VTE) in adults and children. The aim of our study was to evaluate the incidence of VTE in children and adolescents with lymphomas. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. A retrospective analysis based on medical data of 262 children and adolescents (0–18 years) with primary lymphomas (n = 262) who were treated in Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology since 01.01.2013 to 31.12.2019 had been performed. Such parameters as age and sex distribution of patients, the frequency, as well as the cumulative incidence of detection (CI) and differences in localization, the median time of detection of symptomatic (sVTE) and asymptomatic episodes of VT (aVTE), their relationship with central venous catheters (CVC) were analyzed. Statistical processing of the obtained data was carried out using the XLSTAT 2020 program (Addinsoft, France). The median age was 11,1 years (interquartile range (IQR) 6.5–15 years), the ratio of males to females was 2.2:1. There were 71 episodes of VTE in 65 patients (24.8%, 95% confidence interval (CI): 19.6–30). Among all episodes of VTE 31% were defined as sVTE at 400 day CI for sVTE was found to be 8.1% (95% CI: 5.4–12.2) and CI for aVTE – 18.7% (95% CI: 14.4–24.2). The median time to VTE episode was 38 days (IQR 16.5–91.5 days). There was a trend towards an earlier diagnosis of sVTE (median 23.5 days, IQR – 17–42 days) than aVTE (median 62 days, IQR 14–80 days), p = 0.075. VTE was CVC-related in 67.7 of all VTE cases. In one case, asymptomatic thrombosis of right atrium led to pulmonary embolism (PE). VTE is a frequent complication in children and adolescents with lymphomas. Most episodes of VTE were asymptomatic, one of which was the most likely cause of PE in the child. Further research is needed to find risk factors for VTE.


  • Open Access

    The first experience of using MEK inhibitors for type 1 neurofibromatosis in children in the Russian Federation in a hospital for short-term treatment at the National Medical Research Center

    by N. M. Ershov, A. V. Pshonkin, Yu. M. Mareeva, L. A. Yasko, M. V. Kurnikova, D. A. Evstratov, D. A. Gobadze, L. A. Papusha, G. S. Ovsyannikova, A. G. Rumyantsev

    Neurofibromatosis is a genetic disorder that affects the bones, soft tissues, skin, and the nervous system. Neurofibromatosis has been described in 1882, however, there is still no specific treatment for this disease and no treatment protocols for the most frequent and life-threatening complications such as non-malignant tumors deriving from the cells of the peripheral nerve sheaths. Progress in molecular genetic study discovered the underlying genetic alteration in this tumor. This knowledge provides the base for clinical trials with new drugs. MEK-inhibitors are acting on the RAS-MAPK signaling pathway and have shown their efficacy in decreasing the size of inoperable tumors in children with type 1 neurofibromatosis (NF1). Although, this therapy does not completely reduce the tumor volume, it can significantly improve the quality of life. This article presents a clinical case of the trametinib efficacy in a child suffering from NF1-associated plexiform neurofibromas.


  • Open Access

    Atypical aggressive development of pigmented epithelioid melanocytoma in patient with Fanconi Anemia after hematopoietic stem cell transplantation

    by S. A. Radygina, I. S. Kletskaya, I. O. Kostareva, K. V. Mitrakov, S. N. Kozlovskaya, N. M. Ershov, I. P. Shipitsina, D. N. Balashov

    Pigmented epithelioid melanocytoma (PEM) is an uncommon, recently described melanocytic lesion. There is a high rate of regional metastases, but limited evidence of distant metastases, an indolent clinical course and favorable outcome. The article presents a clinical case of PEM with aggressive behavior and distant metastases in patient with Fanconi Anemia after hematopoietic stem cell transplantation. Parents gave their consent to use information about the child, including fotos, in the article.

  • Platelet function and blood coagulation system status in childhood essential thrombocythemia

    by Dmitrii M. Polokhov, Nikolay M. Ershov, Anastasia A. Ignatova, Evgeniya A. Ponomarenko, Marina V. Gaskova, Pavel A. Zharkov, Daria V. Fedorova, Alexandr V. Poletaev, Elena A. Seregina, Galina A. Novichkova, et al.

    Childhood essential thrombocythemia (ET) is a rare chronic myeloproliferative disorder. The quality of life of ET patients may decrease as a result of ischemic and hemorrhagic complications of unclear origin. Our goal was to characterize the hemostatic system in children with ET. We genotyped and investigated blood samples from 20 children with ET in a prospective case series study using platelet aggregation, functional flow cytometry (FC) assay and standard clotting assays. Three children had a JAK2V617F mutation, 4 had mutations in CALR and 13 were triple-negative. Myelofibrosis in stage 1-2 was detected in 3 children. Three patients had bleeding episodes and seven had ischemic events. Aggregation in response to collagen, adenosine diphosphate, and ristomycin was decreased in all patients. In FC, significant changes in the whole patient group compared to the healthy children control group were decrease in the resting forward scatter and PAC1 binding (activated GPIIb/IIIa) level. For the activated platelets, dense granules release (by mepacrine), PAC1, and GPIIb/IIIa levels were significantly decreased. GPIb/V/IX, P-selectin, and phosphatidylserine levels manifested only moderate differences. Forward and side scatter changes in response to stimulation (representing shape change) and dense granules release were significantly lower in the 3 patients with bleeding than in the 17 patients without hemorrhage. Activated partial thromboplastin time was slightly prolonged, prothrombin index was slightly shortened and thrombin time was normal, while fibrinogen was mildly decreased in the ET patients. It could be concluded that the observed platelet function defects could be related to bleeding in ET, and be potentially used as a marker.


  • Open Access

    Efficacy and toxicity of the treatment of children and adolescents with Hodgkin Lymphoma by GPOH-HD-2002 protocol

    by D. A. Evstratov, N. V. Myakova, A. V. Pshonkin, Yu. G. Abugova, Yu. Yu. Dyakonova, S. A. Radygina, N. М. Ershov, Yu. N. Likar, L. A. Potapenko, D. M. Konovalov, et al.

    The reduction of long-term survival and fertility is still a problem in management of Hodgkin lymphoma in children and adolescents. These problems are partly solved by reduction of radiotherapy and changing procarbazine on etoposide and dacarbazine. We analyzed medical data of patients with HL 18 years that were treated by modified OEPA-COPDAC protocol since 1.01.2012 to 01.12.2017. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. All patients despite gender didn't receive procarbazine. We analyzed data of 77 patients. Event-free survival (EFS) was 88% (95% CI 76.2-93.9%). EFS didn't differ between boys and girls 86.9% (95% CI 67.8-94.7%) and 88.7% (95% CI 67.3-96.1%) respectively (р = 0,9). EFS was significantly higher in patients without E-lesions compared with patients with E-lesions 90.8% (95% CI 77.8-96.2) and 72.7% (95% CI 28.4-89.6) respectively (p = 0.04). We analyzed toxicity of 40 cycles OEPA and 44 cycles COPDAC. Toxicity was acceptable. In our study we didn't detect significant difference in EFS in boys and girls. Procarbazine can be safely changed on etoposide in OPPA and dacarbazine in COPP in boys and girls with HL. E-lesions is a risk factor of inferior EFS.


  • VENOUS THROMBOSIS IN CHILDREN AND ADOLESCENTS WITH HODGKIN’S LYMPHOMA

    by Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, D.A. Evstratov, P.A. Zharkov, A.V. Pshonkin, Y.G. Abugova, Y.Y. Dyakonova, N.M. Ershov, L.A. Potapenko, S.A. Radygina, E.V. Feoktistova, et al.

    Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.